Olivier Donnez
Research Subjects
Olivier Donnez has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Jacques Donnez
Department of Gynecology, Université Catholique de Louvain , Brussels
6 shared publications - Marie-Madeleine Dolmans
Gynecology Research Unit, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; Gynecology Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium
3 shared publications Jacques Donnez
Society for Research into Infertility, Brussels, Belgium
2 shared publicationsMarie M Dolmans
2 shared publicationsMarie-Madeleine Dolmans
Pôle de Recherche en Gynécologie, IREC Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; Gynecology Department, Cliniques Universitaires Saint Luc, Brussels, Belgium
2 shared publications- Renan Orellana
Health Sciences Faculty, Bernardo O'Higgins University, General Gana 1702, Santiago, Chile
2 shared publications
Latest Publications
- 3 August 2023
- Published by Elsevier in Best Practice & Research Clinical Obstetrics & Gynaecology
- Vol. 90, 102398
Cesarean scar disorder: Management and repair
- 3 August 2023
- Published by Elsevier in Best Practice & Research Clinical Obstetrics & Gynaecology
- Vol. 90, 102398
Cesarean scar disorder: Management and repair
- Open Access
- 10 December 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (24) , 5794
Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New ’Hit Hard First and then Maintain’ Regimen of Administration
(1) Background: The aim of the present pilot study was to study the effect of a new oral gonadotropin-releasing hormone antagonist on adenomyosis. (2) Methods: Eight premenopausal women, aged between 37 and 45 years, presenting with heavy menstrual bleeding, pelvic pain, and dysmenorrhea due to diffuse and disseminated uterine adenomyosis, confirmed by magnetic resonance imaging (MRI), received 200 mg linzagolix once daily for a period of 12 weeks, after which they were switched to 100 mg linzagolix once daily for another 12 weeks. The primary efficacy endpoint was the change in volume of the adenomyotic uterus from baseline to 24 weeks, evaluated by MRI. Secondary efficacy endpoints included the change in uterine volume from baseline to 12 and 36 weeks by MRI, and also weeks 12, 24, and 36 assessed by transvaginal ultrasound (TVUS). Other endpoints were overall pelvic pain, dysmenorrhea, non-menstrual pelvic pain, dyspareunia, amenorrhea, quality of life measures, bone mineral density (BMD), junctional zone thickness, and serum estradiol values. (3) Results: Median serum estradiol was suppressed below 20 pg/mL during the 12 weeks on linzagolix 200 mg, and maintained below 60 pg/mL during the second 12 weeks on linzagolix 100 mg. At baseline, the mean ± SD uterine volume was 333 ± 250 cm3. After 24 weeks of treatment, it was 204 ± 126 cm3, a reduction of 32% (p = 0.0057). After 12 weeks, the mean uterine volume was 159 ± 95 cm3, a reduction of 55% from baseline (p = 0.0001). A similar pattern was observed when uterine volume was assessed by TVUS. Improvements in overall pelvic pain, dysmenorrhea, non-menstrual pelvic pain, dyspareunia, and dyschezia, as well as quality of life measured using the EHP-30 were also observed. Mean percentage BMD loss at 24 weeks was, respectively, −2.4%, −1.3%, and −4.1% for the spine, femoral neck, and total hip. The most common adverse events were hot flushes, which occurred in 6/8 women during the first 12 weeks, and 1/8 women between 12 and 24 weeks. (4) Conclusions: Linzagolix at a dose of 200 mg/day reduced uterine volume, and improved clinically relevant symptoms. Treatment with 100 mg thereafter retains the therapeutic benefits of the starting dose while minimizing side effects. This ‘hit hard first and then maintain’ approach may be the optimal way to treat women with symptomatic adenomyosis.
- 10 December 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (24) , 5794
Open AccessUterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New ’Hit Hard First and then Maintain’ Regimen of Administration
(1) Background: The aim of the present pilot study was to study the effect of a new oral gonadotropin-releasing hormone antagonist on adenomyosis. (2) Methods: Eight premenopausal women, aged between 37 and 45 years, presenting with heavy menstrual bleeding, pelvic pain, and dysmenorrhea due to diffuse and disseminated uterine adenomyosis, confirmed by magnetic resonance imaging (MRI), received 200 mg linzagolix once daily for a period of 12 weeks, after which they were switched to 100 mg linzagolix once daily for another 12 weeks. The primary efficacy endpoint was the change in volume of the adenomyotic uterus from baseline to 24 weeks, evaluated by MRI. Secondary efficacy endpoints included the change in uterine volume from baseline to 12 and 36 weeks by MRI, and also weeks 12, 24, and 36 assessed by transvaginal ultrasound (TVUS). Other endpoints were overall pelvic pain, dysmenorrhea, non-menstrual pelvic pain, dyspareunia, amenorrhea, quality of life measures, bone mineral density (BMD), junctional zone thickness, and serum estradiol values. (3) Results: Median serum estradiol was suppressed below 20 pg/mL during the 12 weeks on linzagolix 200 mg, and maintained below 60 pg/mL during the second 12 weeks on linzagolix 100 mg. At baseline, the mean ± SD uterine volume was 333 ± 250 cm3. After 24 weeks of treatment, it was 204 ± 126 cm3, a reduction of 32% (p = 0.0057). After 12 weeks, the mean uterine volume was 159 ± 95 cm3, a reduction of 55% from baseline (p = 0.0001). A similar pattern was observed when uterine volume was assessed by TVUS. Improvements in overall pelvic pain, dysmenorrhea, non-menstrual pelvic pain, dyspareunia, and dyschezia, as well as quality of life measured using the EHP-30 were also observed. Mean percentage BMD loss at 24 weeks was, respectively, −2.4%, −1.3%, and −4.1% for the spine, femoral neck, and total hip. The most common adverse events were hot flushes, which occurred in 6/8 women during the first 12 weeks, and 1/8 women between 12 and 24 weeks. (4) Conclusions: Linzagolix at a dose of 200 mg/day reduced uterine volume, and improved clinically relevant symptoms. Treatment with 100 mg thereafter retains the therapeutic benefits of the starting dose while minimizing side effects. This ‘hit hard first and then maintain’ approach may be the optimal way to treat women with symptomatic adenomyosis.
- Open Access
- 5 November 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (21) , 5183
Conservative Management of Rectovaginal Deep Endometriosis: Shaving Should Be Considered as the Primary Surgical Approach in a High Majority of Cases
Deep endometriosis infiltrating the rectum remains a challenging situation to manage, and it is even more important when ureters and pelvic nerves are also infiltrated. Removal of deep rectovaginal endometriosis is mandatory in case of symptoms strongly impairing quality of life, alteration of digestive, urinary, sexual and reproductive functions, or in case of growing. Extensive preoperative imaging is required to choose the right technique between laparoscopic shaving, disc excision, or rectal resection. When performed by skilled surgeons and well-trained teams, a very high majority of cases of deep endometriosis nodule (>95%) is feasible by the shaving technique, and this is associated with lower complication rates regarding rectal resection. In most cases, removing a part of the rectum is questionable according to the risk of complications, and the rectum should be preserved as far as possible. Shaving and rectal resection are comparable in terms of recurrence rates. As shaving is manageable whatever the size of the lesions, surgeons should consider rectal shaving as first-line surgery to remove rectal deep endometriosis. Rectal stenosis of more than 80% of the lumen, multiple bowel deep endometriosis nodules, and stenotic sigmoid colon lesions should be considered as indication for rectal resection, but this represents a minority of cases.
- 5 November 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (21) , 5183
Open AccessConservative Management of Rectovaginal Deep Endometriosis: Shaving Should Be Considered as the Primary Surgical Approach in a High Majority of Cases
Deep endometriosis infiltrating the rectum remains a challenging situation to manage, and it is even more important when ureters and pelvic nerves are also infiltrated. Removal of deep rectovaginal endometriosis is mandatory in case of symptoms strongly impairing quality of life, alteration of digestive, urinary, sexual and reproductive functions, or in case of growing. Extensive preoperative imaging is required to choose the right technique between laparoscopic shaving, disc excision, or rectal resection. When performed by skilled surgeons and well-trained teams, a very high majority of cases of deep endometriosis nodule (>95%) is feasible by the shaving technique, and this is associated with lower complication rates regarding rectal resection. In most cases, removing a part of the rectum is questionable according to the risk of complications, and the rectum should be preserved as far as possible. Shaving and rectal resection are comparable in terms of recurrence rates. As shaving is manageable whatever the size of the lesions, surgeons should consider rectal shaving as first-line surgery to remove rectal deep endometriosis. Rectal stenosis of more than 80% of the lumen, multiple bowel deep endometriosis nodules, and stenotic sigmoid colon lesions should be considered as indication for rectal resection, but this represents a minority of cases.
- Top Cited Papers
- 1 April 2020
- Published by Elsevier in Fertility and Sterility
- Vol. 113 (4) , 704-716
Cesarean scar defects: management of an iatrogenic pathology whose prevalence has dramatically increased
- 1 April 2020
- Published by Elsevier in Fertility and Sterility
- Vol. 113 (4) , 704-716
Top Cited PapersCesarean scar defects: management of an iatrogenic pathology whose prevalence has dramatically increased
- 5 October 2018
- Published by Elsevier
- p. 513-524
Uterine Fibroids and Infertility
- 1 January 2018
- Published by Elsevier in Best Practice & Research Clinical Obstetrics & Gynaecology
- Vol. 46, 57-65
The current place of medical therapy in uterine fibroid management
- 1 January 2018
- Published by Elsevier in Best Practice & Research Clinical Obstetrics & Gynaecology
- Vol. 46, 57-65
The current place of medical therapy in uterine fibroid management
- Top Cited Papers
- 1 December 2017
- Published by Elsevier in Fertility and Sterility
- Vol. 108 (6) , 931-942
Choosing the right surgical technique for deep endometriosis: shaving, disc excision, or bowel resection?
- 1 December 2017
- Published by Elsevier in Fertility and Sterility
- Vol. 108 (6) , 931-942
Top Cited PapersChoosing the right surgical technique for deep endometriosis: shaving, disc excision, or bowel resection?
- 1 May 2017
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 72 (5) , 283-284
Gynecological and Obstetrical Outcomes After Laparoscopic Repair of a Cesarean Scar Defect in a Series of 38 Women
(ed from Fertil Steril 2017;107:289–296) As the number of cesarean deliveries has continued to rise worldwide in recent decades, cesarean scar defects have been increasingly described.
- 1 May 2017
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 72 (5) , 283-284
Gynecological and Obstetrical Outcomes After Laparoscopic Repair of a Cesarean Scar Defect in a Series of 38 Women
(ed from Fertil Steril 2017;107:289–296) As the number of cesarean deliveries has continued to rise worldwide in recent decades, cesarean scar defects have been increasingly described.
- Top Cited Papers
- 1 January 2017
- Published by Elsevier in Fertility and Sterility
- Vol. 107 (1) , 289-296.e2
Gynecological and obstetrical outcomes after laparoscopic repair of a cesarean scar defect in a series of 38 women
- 1 January 2017
- Published by Elsevier in Fertility and Sterility
- Vol. 107 (1) , 289-296.e2
Top Cited PapersGynecological and obstetrical outcomes after laparoscopic repair of a cesarean scar defect in a series of 38 women
- 1 March 2016
- Vol. 68 (3) , 313-20
The place of selective progesterone receptor modulators in myoma therapy.
Uterine fibroids are the most commonly encountered benign uterine tumors in women of reproductive age. As progesterone is known to play a key role in promoting myoma growth, the goal of the study was to analyze the efficacy of selective progesterone receptor modulators (SPRMs). From four studies, it was concluded that UPA (ulipristal acetate) treatment was able to control myoma-associated uterine bleeding in over 90% of cases and significantly reduce myoma volume in more than 80% of women. The results of long-term intermittent therapy (PEARL III and PEARL IV studies) (4 courses of 3 months) demonstrated that more than one course of UPA is able to maximize its potential benefits in terms of control of bleeding and fibroid volume reduction. The treatment was considered safe, even at the level of endometrial changes. With the advent of SPRMs, new algorithms should be discussed, as there is no doubt that there is a place for medical therapy with SPRMs in the current armamentarium of fibroid management.
- 1 March 2016
- Vol. 68 (3) , 313-20
The place of selective progesterone receptor modulators in myoma therapy.
Uterine fibroids are the most commonly encountered benign uterine tumors in women of reproductive age. As progesterone is known to play a key role in promoting myoma growth, the goal of the study was to analyze the efficacy of selective progesterone receptor modulators (SPRMs). From four studies, it was concluded that UPA (ulipristal acetate) treatment was able to control myoma-associated uterine bleeding in over 90% of cases and significantly reduce myoma volume in more than 80% of women. The results of long-term intermittent therapy (PEARL III and PEARL IV studies) (4 courses of 3 months) demonstrated that more than one course of UPA is able to maximize its potential benefits in terms of control of bleeding and fibroid volume reduction. The treatment was considered safe, even at the level of endometrial changes. With the advent of SPRMs, new algorithms should be discussed, as there is no doubt that there is a place for medical therapy with SPRMs in the current armamentarium of fibroid management.